drugset / Trial / NCT03336619

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

NCT03336619

Phase 3 Completed 1030 enrolled Romark Laboratories L.C.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.

Timeline

Start
2018-01-17
Primary completion
2019-04-17
Completion
2019-04-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitazoxanide Other / unclassified 600 mg Oral

Indications